This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Exact Sciences Finds its Mojo

MADISON, Wis. ( TheStreet) -- After years of stumbles, Exact Sciences (EXAS - Get Report) looks to be on the right path towards developing a commercially successful, stool-based genetic screening test for colon cancer.

I spent some time with Exact's new CEO Kevin Conroy last week in San Francisco and walked away impressed. Exact was probably the best small-cap stock story I heard during four days of meetings and presentations tied to the J.P. Morgan Healthcare Conference.

Shares of Exact Sciences are up almost 70% since the middle of December, when analysts at Baird reinitiated research coverage with an outperform rating and a $5 price target. The stock closed Wednesday at $4.20.

Exact was limping along unnoticed for quite some time, but Conroy is putting the company back on the Wall Street's radar. Investors should have reason again to get excited about the company's commercial prospects for an easy-to-use, non-invasive molecular test that will help doctors screen more patients for early-stage colon cancer -- and perhaps save lives in the process.

Results from the first outside validation of Exact's new gene test for colon cancer are expected in the second half of the year. If this study confirms the accuracy of the test, Exact plans to start a pivotal clinical study in 2011.

Exact estimates that the commercial market opportunity for its new colon cancer test to be about $1.2 billion, based on a conservative 30% share of the overall colon cancer-screening market.

Colon cancer is the second-deadliest cancer in the U.S., causing almost 50,000 deaths annually. Yet it isn't particularly aggressive, and in fact, if diagnosed early, surgical removal of the tumor usually leads to very high long-term survival rates.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
EXAS $23.93 9.30%
HOLX $32.31 -0.14%
LH $121.99 -1.50%
SQNM $3.62 -0.82%
AAPL $127.72 -0.64%

Markets

DOW 18,031.68 -104.04 -0.57%
S&P 500 2,101.04 +2.51 0.12%
NASDAQ 4,982.8090 +15.6680 0.32%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs